Email Facebook Twitter

ETF Investing made simple; CEO of justETF explains why Watch here

ETF Investing made simple; CEO of justETF explains why

Member Info for inanaco

Premium Member

Send a private message to inanaco

Member Since: Wed, 19th Oct 2011

Number of Share Chat Posts (all time): 24,302
Number of Share Chat Posts (last 30 days): 670

Last Posted: Today 16:21

Post Distribution over the last 30 days

Today 16:21

but you just posted

""" Think it's really important to keep expectations at a realistic level so that if an RNS lands announcing funding at a small discount, holders will accept it for what it is - normal.

then you stated .......... """ I'm holding because I believe they are worth far more than the market's valuation""

so what is a realistic level ??? ......... do you see the problem here ?
Today 15:51

But your posts rather than explaining what we have and its true value, indicates you accept the markets valuation and ignore all data presented.
If scancell does raise funds below the current SP at what point do you draw the line ......... 17p ... 15p ... 14p ?
you see the issue here or not ? the market will constantly move down to what ever negative overtones is thrown at it all you are doing is helping Agema buy at 9p

you posted

"""" Think it's really important to keep expectations at a realistic level so that if an RNS lands announcing funding at a small discount, holders will accept it for what it is - normal. """"

it just makes no sense against what Scancell is saying

and its impossible to define the base line
Today 15:23

Land grab ..........

the reason why Scancell is running with PD1 is because it needs that visible element in late stage with immunobody to get across the important commercial value of it ........

but its real target is adjuvant after surgery not late stage progression with PD1

PD1 will never be the back bone because its to systemic it's influence is whole body and will continue with toxicity issues.

Moditope will become the back bone of late stage ......... single injection, "mouse will not die"
that is what Richard is referring to .....

The market has not understood the havoc that will be thrust on Big Pharma Balance sheets by Moditope

single injection targeted at the cancer with no systemic problems.

many of these current thinkers trying to work out what is and what might be, really are not researching well enough.

Lindy has declared from blood cancers to solid cancers and even cold cancers with combos with moditope ...

the game is in play, we have the entire market to ourselves .............

adjuvant with Immunobody

late stage with Moditope
Today 14:59

Why produce the Hardman report, very comprehensive and expensive document ?

clearly indicating the miss match to SP .........via comparing to other BIO ... the science and how it all fits together

clearly directed at Investors or Future investment

these all indicate that scancell is not looking for funding at any price, but is looking for funding or deals that enhance share holder value
Today 14:47

Fluffs his lines ........ nominated for "clapping" and making a Jolly noise ..... when " £1 on the cards" hits target
Today 14:41

to oldernotwiser Included this statement ............

FWIW, I do agree that if Scancell go down the route of an equity funding then it's highly likely that will be at a discount to the SP and therefore that there may be an initial fall. The point I was really trying to get across is that it could/should/will also be the trigger for the long awaited SP recovery.

All IMO of course.

what i am showing here is ....... Scancell already know the SP has not matched accumulated value, so why would they raise significant funds at a discount ??

can you explain that for me. Thanks
Today 14:23

its word play i know...........

but you dont need any more words in the RNS over and above "in active discussion"
Today 14:20

have i achieved clarification ? on my point
Today 14:05

which means ......... to show value ......they raise funds above the current SP or ..... they close Off a deal ..

Jan 31st RNS

is currently engaged in active discussions with several companies on both platforms. Closing a significant commercial arrangement with one or more of these companies would go a long way to underpin the value of these assets.


strange word to use unless your close, because they already used active, so why add that extra line, its not needed

then why add "significant" .......... that's an end game statement that you know the numbers are looking interesting
Today 14:03

a conflict has been created by two statements in the same RNS ...........

Shareprice verse Accumulated value


funding .........

Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days

Member Login

Forgotten your password?


Don't have an account? Click here to Register Free!

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.